<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "9: future funds", fill: "#5f9ea0"},
{source: "9: future funds", target: "9: largely on", fill: "#5f9ea0"},
{source: "9: largely on", target: "9: potential future collaborations", fill: "#5f9ea0"},
{source: "9: future funds", target: "10: whether additional financing will", fill: "#ffd300"},
{source: "10: whether additional financing will", target: "10: financing on terms", fill: "#ffd300"},
{source: "10: financing on terms", target: "10: stockholders", fill: "#ffd300"},
{source: "10: whether additional financing will", target: "11: expenditures", fill: "#f7e98e"},
{source: "11: expenditures", target: "11: increase over", fill: "#f7e98e"},
{source: "11: increase over", target: "11: next several", fill: "#f7e98e"},
{source: "11: next several", target: "11: infrastructure", fill: "#f7e98e"},
{source: "11: infrastructure", target: "11: development", fill: "#f7e98e"},
{source: "11: development", target: "11: activities", fill: "#f7e98e"},
{source: "11: expenditures", target: "12: licensing agreement with", fill: "#4d5d53"},
{source: "12: licensing agreement with", target: "12: commercialize", fill: "#4d5d53"},
{source: "12: commercialize", target: "12: candidates", fill: "#4d5d53"},
{source: "12: candidates", target: "12: kinase inhibitor program which", fill: "#4d5d53"},
{source: "12: licensing agreement with", target: "16: additional", fill: "#003153"},
{source: "16: additional", target: "16: collaboration", fill: "#003153"},
{source: "16: collaboration", target: "16: arrangements", fill: "#003153"},
{source: "16: arrangements", target: "16: relinquish", fill: "#003153"},
{source: "16: relinquish", target: "16: technologies", fill: "#003153"},
{source: "16: technologies", target: "16: candidates", fill: "#003153"},
{source: "16: additional", target: "18: future funding requirements will depend upon", fill: "#a8e4a0"},
{source: "18: future funding requirements will depend upon", target: "18: preclinical studies", fill: "#a8e4a0"},
{source: "18: preclinical studies", target: "18: manufacture", fill: "#a8e4a0"},
{source: "18: manufacture", target: "18: clinical trials", fill: "#a8e4a0"},
{source: "18: clinical trials", target: "18: product candidates", fill: "#a8e4a0"},
{source: "18: product candidates", target: "18: conducted by us", fill: "#a8e4a0"},
{source: "18: conducted by us", target: "18: collaborative partners", fill: "#a8e4a0"},
{source: "18: collaborative partners", target: "18: establish new collaborations", fill: "#a8e4a0"},
{source: "18: establish new collaborations", target: "18: existing collaboration partnerships", fill: "#a8e4a0"},
{source: "18: existing collaboration partnerships", target: "18: development programs", fill: "#a8e4a0"},
{source: "18: development programs", target: "18: milestones", fill: "#a8e4a0"},
{source: "18: milestones", target: "18: agreements", fill: "#a8e4a0"},
{source: "18: agreements", target: "18: trigger payments", fill: "#a8e4a0"},
{source: "18: trigger payments", target: "18: development efforts", fill: "#a8e4a0"},
{source: "18: development efforts", target: "18: technologies", fill: "#a8e4a0"},
{source: "18: technologies", target: "18: competing technological", fill: "#a8e4a0"},
{source: "18: competing technological", target: "18: market developments", fill: "#a8e4a0"},
{source: "18: market developments", target: "18: intellectual rights", fill: "#a8e4a0"},
{source: "18: intellectual rights", target: "18: regulatory approvals", fill: "#a8e4a0"},
{source: "18: regulatory approvals", target: "18: filings by us", fill: "#a8e4a0"},
{source: "18: filings by us", target: "18: collaborators", fill: "#a8e4a0"},
{source: "18: collaborators", target: "18: expenses associated with unforeseen litigation", fill: "#a8e4a0"},
{source: "18: future funding requirements will depend upon", target: "74: into new collaborations", fill: "#df00ff"},
{source: "74: into new collaborations", target: "74: collaborations", fill: "#df00ff"},
{source: "74: collaborations", target: "74: highly uncertain", fill: "#df00ff"},
{source: "74: into new collaborations", target: "START_HERE", fill: "#df00ff"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kevin_Smith">Kevin Smith</a></td>
      <td>Kevin Patrick Smith (born August 2, 1970) is an American filmmaker, actor, comedian, comic book writer, author, YouTuber, and podcaster. He came to prominence with the low-budget comedy buddy film Clerks (1994), which he wrote, directed, co-produced, and acted in as the character Silent Bob of stoner duo Jay and Silent Bob, characters who also appeared in Smith's later films Mallrats (1995), Chasing Amy (1997), Dogma (1999), Jay and Silent Bob Strike Back (2001), Clerks II (2006), and Jay and Silent Bob Reboot (2019), which are set primarily in his home state of New Jersey.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Document_collaboration">Document collaboration</a></td>
      <td>Document and file collaboration are the tools or systems set up to help multiple people work together on a single document or file to achieve a single final version. Normally, this is software that allows teams to work on a single document, such as a word processor document, at the same time from different computer terminals or mobile devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration_with_the_Axis_powers">Collaboration with the Axis powers</a></td>
      <td>Within nations occupied by the Axis powers in World War II, some citizens and organizations, prompted by nationalism, ethnic hatred, anti-communism, antisemitism, opportunism, self-defense, or often a combination, knowingly collaborated with the Axis Powers. Some of these collaborators committed war crimes, crimes against humanity, or atrocities in the Holocaust.Collaboration has been defined as cooperation between elements of the population of a defeated state and representatives of the victorious power.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborators_(Battlestar_Galactica)">Collaborators (Battlestar Galactica)</a></td>
      <td>"Collaborators"  is the fifth episode of the third season from the science fiction television series Battlestar Galactica.\nThis is the first episode of season 3 to include a survivor count, at 41,435, down considerably from the 49,550 shown in "Lay Down Your Burdens" (Part 2).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/No.6_Collaborations_Project">No.6 Collaborations Project</a></td>
      <td>No. 6 Collaborations Project is the fourth studio album and second collaboration project by English singer-songwriter Ed Sheeran.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_film_director_and_actor_collaborations">List of film director and actor collaborations</a></td>
      <td>Some film directors and actors have collaborated numerous times and have become noteworthy for their partnerships. Note: In some instances, the body of work is too extensive to list all the films on which they worked together.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/No._5_Collaborations_Project">No. 5 Collaborations Project</a></td>
      <td>No. 5 Collaborations Project is an extended play (EP) by British singer-songwriter Ed Sheeran.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborations_2">Collaborations 2</a></td>
      <td>Collaborations 2 is the tenth studio album by Punjabi singer Sukshinder Shinda, released on 26 February 2009 worldwide making his second collaborated album. The album was also released internationally to USA, Canada, and U.K.The album was preceded by the lead single, Ghum Shum Ghum Shum which featured Rahat Fateh Ali Khan.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>RIGEL PHARMACEUTICALS INC      Item 1A Risk Factors       In evaluating our business, you <font color="blue">should carefully</font> consider the following     risks, as well as the other information contained in this annual report on     Form 10-K If any of the <font color="blue">following risks actually</font> occurs, our business could     be harmed</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue"><font color="blue">uncertainties</font> described</font> below are not the only ones     <font color="blue">facing us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to us, or     that we currently see as immaterial, may also harm our business</td>
    </tr>
    <tr>
      <td>We will need <font color="blue"><font color="blue">additional</font> capital</font> in the future to <font color="blue">sufficiently fund</font> our     <font color="blue">operations</font> and research</td>
    </tr>
    <tr>
      <td>We have consumed substantial amounts of capital to date, and operating     <font color="blue"><font color="blue">expenditure</font>s</font>  are expected to <font color="blue">increase over</font> the <font color="blue"><font color="blue">next several</font> years</font></td>
    </tr>
    <tr>
      <td>In     July 2005, we completed a public offering in which we sold 4cmam197cmam500 shares     of our <font color="blue">common stock</font>, including 547cmam500 shares issued upon exercise of an     <font color="blue">option granted</font> to the <font color="blue">underwriters</font> to cover over-allotments, at a price to     the public of dlra20dtta75 per share, which resulted in net proceeds to us of     approximately dlra81dtta6 million after <font color="blue">deducting underwriting discounts</font> and     <font color="blue">commissions</font> and related expenses</td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">existing capital</font>     resources and anticipated <font color="blue">proceeds from current <font color="blue">collaboration</font>s will</font> be     sufficient to support our current operating plan <font color="blue">through at least</font> the next     12 months</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> will require <font color="blue"><font color="blue">significant</font> <font color="blue">additional</font> funding</font> in     large part due to our research and <font color="blue">development</font> expenses, future preclinical     and clinical-<font color="blue">testing costs</font>, and the absence of any <font color="blue">meaningful revenues</font> for     the  <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The amount of <font color="blue">future funds</font> needed will depend     <font color="blue">largely on</font> the timing and structure of <font color="blue">potential future <font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>We     do not know <font color="blue">whether <font color="blue">additional</font> financing will</font> be available when needed, or     that, if available, we will obtain <font color="blue">financing on terms</font> favorable to our     <font color="blue">stockholders</font> or us</td>
    </tr>
    <tr>
      <td>We have consumed substantial amounts of capital to date,     and operating <font color="blue"><font color="blue">expenditure</font>s</font> are expected to <font color="blue">increase over</font> the <font color="blue">next several</font>     years  as  we  expand  our <font color="blue">infrastructure</font> and research and <font color="blue">development</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>On October 24, 2005, we signed a <font color="blue">licensing <font color="blue">agreement</font> with</font> Serono that grants     to  Serono  an  exclusive license to develop and <font color="blue">commercialize</font> product     <font color="blue">candidates</font> from our Aurora kinase inhibitor program, which includes R763</td>
    </tr>
    <tr>
      <td>Under the terms of the <font color="blue">agreement</font>, we received <font color="blue">initial payments totaling</font>     dlra25dtta0 million, comprised of a <font color="blue">license fee</font> of dlra10dtta0 million and the purchase     of dlra15dtta0 million of our <font color="blue">common stock</font>, at a premium</td>
    </tr>
    <tr>
      <td><font color="blue">During February </font>2006, we     received a <font color="blue">milestone payment</font> of dlra5dtta0 million triggered by the <font color="blue">regulatory</font>     <font color="blue">acceptance</font> of the R763 IND in January 2006</td>
    </tr>
    <tr>
      <td>To the extent we raise <font color="blue"><font color="blue">additional</font> capital</font> by issuing equity securities, our     <font color="blue">stockholders</font> could at that time experience substantial dilution</td>
    </tr>
    <tr>
      <td>To the     extent that we raise <font color="blue">additional</font> funds through <font color="blue">collaboration</font> and licensing     <font color="blue">arrangements</font>,  we  may  be  required  to <font color="blue">relinquish</font> some rights to our     <font color="blue">technologies</font> or product <font color="blue">candidates</font>, or grant licenses on terms that are not     favorable to us</td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________       Our <font color="blue">future funding <font color="blue">requirements</font> will depend on</font> many <font color="blue">uncertain factors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future funding <font color="blue">requirements</font> will depend upon</font> many factors, including,     but not limited to:       ·       the progress and success of <font color="blue">pre<font color="blue">clinical studies</font></font> (including studies     and <font color="blue">manufacture</font> of materials) and <font color="blue">clinical trials</font> of our product <font color="blue">candidates</font>     <font color="blue">conducted by us</font> or our <font color="blue"><font color="blue">collaborative</font> partners</font> or licensees;       ·       our ability to establish new <font color="blue">collaboration</font>s and to maintain our     existing <font color="blue">collaboration</font> partnerships;       ·       the progress of <font color="blue">research programs</font> carried out by us;       ·       any changes in the breadth of our research and <font color="blue">development</font> programs;       ·       our ability to meet the <font color="blue">milestones</font> identified in our <font color="blue">collaborative</font>     <font color="blue">agreement</font>s that <font color="blue">trigger payments</font>;       ·        the  progress  of the research and <font color="blue">development</font> efforts of our     <font color="blue"><font color="blue">collaborative</font> partners</font>;       ·       our ability to acquire or license other <font color="blue">technologies</font> or compounds     that we seek to pursue;       ·       our ability to manage our growth;       ·       <font color="blue">competing technological</font> and market <font color="blue">development</font>s;       ·       the costs and timing of obtaining, enforcing and defending our     patent and <font color="blue"><font color="blue">intellectual</font> rights</font>;       ·       the costs and timing of <font color="blue">regulatory</font> approvals and <font color="blue">filings by us</font> and     our <font color="blue"><font color="blue">collaborator</font>s</font>; and       ·       <font color="blue">expenses <font color="blue">associated with</font> unforeseen <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Insufficient </font>funds may require us to delay, scale back or eliminate some or     all of our research or <font color="blue">development</font> programs, to <font color="blue">lose <font color="blue">rights under</font> existing</font>     licenses or to <font color="blue">relinquish</font> greater or all rights to product <font color="blue">candidates</font> at an     earlier  stage of <font color="blue">development</font> or on less favorable terms than we would     <font color="blue">otherwise choose</font> or <font color="blue">may <font color="blue">adversely affect</font></font> our ability to operate as a going     concern</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success as</font> a company is <font color="blue">uncertain due</font> to our history of operating losses     and the <font color="blue">uncertainty</font> of <font color="blue">future <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>Due in large part to the <font color="blue"><font color="blue">significant</font> research</font> and <font color="blue">development</font> <font color="blue"><font color="blue">expenditure</font>s</font>     required to identify and validate new product <font color="blue">candidates</font> and pursue our     <font color="blue">development</font> efforts, we have not <font color="blue">been profitable</font> and have incurred operating     <font color="blue">losses since</font> we were <font color="blue">incorporated</font> in June 1996</td>
    </tr>
    <tr>
      <td>The extent of our future     losses and the timing of <font color="blue">potential <font color="blue">profitability</font></font> are <font color="blue">highly uncertain</font>, and     we  may never achieve profitable <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Currently, our revenues are generated solely from research payments pursuant     to  our  <font color="blue">collaboration</font> <font color="blue">agreement</font>s and licenses and are insufficient to     generate  profitable  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As  of <font color="blue">December </font>31, 2005, we had an     <font color="blue">accumulated deficit</font> of approximately dlra257dtta5 million</td>
    </tr>
    <tr>
      <td>We expect to incur     losses for at least the <font color="blue"><font color="blue">next several</font> years</font> and expect that these losses     <font color="blue">could increase as</font> we expand our research and <font color="blue">development</font> <font color="blue">activities</font> and     <font color="blue">incur <font color="blue">significant</font> clinical</font> and <font color="blue">testing costs</font></td>
    </tr>
    <tr>
      <td>There is a high risk that <font color="blue">drug discovery</font> and <font color="blue">development</font> efforts might not     <font color="blue"><font color="blue">successfully</font> generate</font> good product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>At the present time, the majority of our <font color="blue">operations</font> are in various stages of     drug <font color="blue">identification</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">two <font color="blue">product compounds</font></font>     in the <font color="blue">clinical testing</font> stage: one is for RA, which is <font color="blue">proprietary</font> to our     Company and the other is for oncology, which is <font color="blue">partnered with</font> SeroNodtta In     our  industry, it is <font color="blue">statistically unlikely</font> that the limited number of     compounds that we have identified as potential product <font color="blue">candidates</font> will     <font color="blue">actually lead</font> to successful product <font color="blue">development</font> efforts, and we do not     expect any drugs resulting from our research to be <font color="blue">commercially available</font>     for <font color="blue">several years</font>, if at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product compounds</font> in the clinic and our     <font color="blue">future leads</font> for <font color="blue"><font color="blue">potential drug</font> compounds</font> are subject to the risks       13     ______________________________________________________________________       and <font color="blue">failures inherent</font> in the <font color="blue">development</font> of <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>risks include, but are not limited to, the <font color="blue">inherent <font color="blue">difficult</font>y</font> in selecting     the right drug and <font color="blue">drug target</font> and <font color="blue">avoiding unwanted</font> side <font color="blue">effects as well as</font>     <font color="blue">unanticipated problems</font> relating to product <font color="blue">development</font>, testing, <font color="blue">regulatory</font>     compliance, manufacturing, marketing, competition and costs and expenses     that <font color="blue">may exceed current</font> estimates</td>
    </tr>
    <tr>
      <td>The results of <font color="blue">preliminary</font> studies do not     <font color="blue">necessarily predict clinical</font> or <font color="blue">commercial success</font>, and larger later-stage     <font color="blue">clinical trials</font> may fail to confirm the results observed in the <font color="blue">preliminary</font>     studies</td>
    </tr>
    <tr>
      <td>With  respect  to  our own compounds in <font color="blue">development</font>, we have     established anticipated timelines for clinical <font color="blue">development</font> based on existing     knowledge of the compound</td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot provide assurance</font> that we will     meet any of these <font color="blue">timelines <font color="blue">with respect</font></font> to the <font color="blue">initiation</font> or <font color="blue">completion</font> of     <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">December </font></font>2005, we completed a Phase 2 trial of R112 for     the  treatment of <font color="blue">allergic rhinitis</font>, which did not achieve the primary     endpoint</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">uncertainty</font> of whether the <font color="blue">accumulated preclinical evidence</font>     (pharmacokinetic, pharmacodynamic, safety and/or other factors) or early     clinical results will be observed in later <font color="blue">clinical trials</font>, we can make no     assurance regarding the likely results from our future <font color="blue">clinical trials</font> or     the impact of those results on our business</td>
    </tr>
    <tr>
      <td>We might not be able to <font color="blue">commercialize</font> our product <font color="blue">candidates</font> <font color="blue">successfully</font> if     problems arise in the <font color="blue">clinical testing</font> and <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization  </font>of  our  product <font color="blue">candidates</font> depends upon successful     <font color="blue">completion</font> of <font color="blue">pre<font color="blue">clinical studies</font></font> and <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Pre<font color="blue">clinical testing</font>     and clinical <font color="blue">development</font> are long, expensive and <font color="blue">uncertain processes</font></td>
    </tr>
    <tr>
      <td>We do     not know whether we, or any of our <font color="blue"><font color="blue">collaborative</font> partners</font>, will be permitted     to undertake <font color="blue">clinical trials</font> of <font color="blue">potential products beyond</font> the <font color="blue">trials already</font>     concluded  and the <font color="blue">trials currently</font> in process</td>
    </tr>
    <tr>
      <td>It will take us or our     <font color="blue"><font color="blue">collaborative</font> partners</font> <font color="blue">several years</font> to complete any <font color="blue">such testing</font>, and     failure can occur at any stage of testing</td>
    </tr>
    <tr>
      <td>Interim results of trials do not     <font color="blue">necessarily predict final</font> results, and acceptable results in <font color="blue">early trials</font>     may  not  be  repeated  in  <font color="blue">later trials</font></td>
    </tr>
    <tr>
      <td>A number of companies in the     <font color="blue"><font color="blue">pharmaceutical</font> industry</font>, including <font color="blue">bio<font color="blue">technology</font> companies</font>, have suffered     <font color="blue"><font color="blue">significant</font> setbacks</font> in advanced <font color="blue">clinical trials</font>, even after achieving     promising results in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>Moreover, we or our <font color="blue">collaborative</font>     partners or <font color="blue">regulators may decide</font> to discontinue <font color="blue">development</font> of any or all     of these projects at any time for commercial, scientific or other reasons</td>
    </tr>
    <tr>
      <td>For example, in <font color="blue">December </font>2005, we completed <font color="blue">Phase II </font>trial of R112 for the     treatment of <font color="blue">allergic rhinitis</font>, which did not achieve the <font color="blue">primary endpoint</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>delays in <font color="blue">clinical testing</font> could materially impact our product     <font color="blue">development</font> costs</td>
    </tr>
    <tr>
      <td>We do not know whether planned <font color="blue">clinical trials</font> will begin     on  time,  will  need to be halted or revamped or will be completed on     schedule,  or  at all</td>
    </tr>
    <tr>
      <td>Clinical trials can be delayed for a variety of     reasons, including delays in obtaining <font color="blue">regulatory</font> approval to commence a     study, delays from scale up delays in reaching <font color="blue">agreement</font> on acceptable     clinical study <font color="blue">agreement</font> terms with <font color="blue">prospective clinical site</font>s, delays in     obtaining  <font color="blue">institutional review board approval</font> to conduct a study at a     <font color="blue">prospective clinical site</font> or delays in <font color="blue">recruiting subjects</font> to <font color="blue">participate</font> in     a study</td>
    </tr>
    <tr>
      <td><font color="blue">Environmental </font><font color="blue"><font color="blue">conditions</font> may impact</font> the execution of some clinical     trials, <font color="blue">particularly</font> during the <font color="blue">allergy season</font> for our <font color="blue">allergic rhinitis</font>     program</td>
    </tr>
    <tr>
      <td>In addition, we typically rely on third-party clinical investigators to     conduct our <font color="blue">clinical trials</font> and other third-party <font color="blue">organizations</font> to oversee     the <font color="blue">operations</font> of such trials and to perform <font color="blue">data collection</font> and analysis</td>
    </tr>
    <tr>
      <td>As a result, we may face <font color="blue">additional</font> delaying factors outside our control if     these parties do not perform their <font color="blue">obligations</font> in a <font color="blue">timely fashion</font></td>
    </tr>
    <tr>
      <td>While we     have not yet experienced delays that have <font color="blue">materially impacted</font> our clinical     trials or product <font color="blue">development</font> costs, delays of this sort could occur for the     reasons identified above or other reasons</td>
    </tr>
    <tr>
      <td>If we have delays in testing or     approvals, our product <font color="blue">development</font> costs will increase</td>
    </tr>
    <tr>
      <td>For example, we may     need  to  make  <font color="blue">additional</font>  payments  to third-party investigators and     <font color="blue">organizations</font> to retain their services or we may need to <font color="blue">pay recruitment</font>     <font color="blue">incentives</font></td>
    </tr>
    <tr>
      <td>If the       14     ______________________________________________________________________       delays are <font color="blue">significant</font>, our financial results and the <font color="blue">commercial prospects</font>     for  our  product <font color="blue">candidates</font> will be harmed, and our ability to become     <font color="blue">profitable will</font> be delayed</td>
    </tr>
    <tr>
      <td>We lack the <font color="blue">capability</font> to <font color="blue">manufacture</font> compounds for <font color="blue">development</font> and rely on     <font color="blue">third parties</font> to <font color="blue">manufacture</font> our product <font color="blue">candidates</font>, and we may be unable to     obtain required material in a <font color="blue">timely manner</font>, at an acceptable cost or at a     <font color="blue">quality level</font> required to receive <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>We currently do not have <font color="blue">manufacturing capabilities</font> or experience <font color="blue">necessary</font>     to produce our product <font color="blue">candidates</font>, including R788 for pre<font color="blue">clinical testing</font>     and <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on</font> a single <font color="blue">manufacture</font>r for R788 product for preclinical     and <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>We will rely on <font color="blue">manufacture</font>rs to deliver materials on     a  <font color="blue">timely basis</font> and to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>,     including the US Food and Drug Administration’s, or FDA’s current Good     <font color="blue">Manufacturing </font>Practices, or GMP These <font color="blue">outsourcing efforts <font color="blue">with respect</font></font> to     <font color="blue">manufacturing preclinical</font> and <font color="blue">clinical supplies will</font> result in a dependence     on our suppliers to timely <font color="blue">manufacture</font> and deliver <font color="blue">sufficient quantities</font> of     materials produced under GMP <font color="blue">conditions</font> to <font color="blue">enable us</font> to conduct planned     <font color="blue">pre<font color="blue">clinical studies</font></font>, <font color="blue">clinical trials</font> and, if possible, to <font color="blue">bring products</font> to     market in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Our  current  and anticipated <font color="blue">future dependence upon</font> these third-party     <font color="blue">manufacture</font>rs <font color="blue">may <font color="blue">adversely affect</font></font> our ability to develop and <font color="blue">commercialize</font>     product <font color="blue">candidates</font> on a timely and <font color="blue"><font color="blue">competitive</font> basis</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">manufacture</font>rs     may  not  be able to produce material on a <font color="blue">timely basis</font> or <font color="blue">manufacture</font>     material  at the <font color="blue">quality level</font> or in the quantity required to meet our     <font color="blue">development</font> timelines and applicable <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We may not be     able  to  maintain  or  renew  our  existing third-party manufacturing     <font color="blue">arrangements</font>, or enter into new <font color="blue">arrangements</font>, on acceptable terms, or at     all</td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue">manufacture</font>rs could terminate or decline to renew our     manufacturing <font color="blue">arrangements</font> based on their own business priorities, at a time     that is costly or <font color="blue">inconvenient</font> for us</td>
    </tr>
    <tr>
      <td>If we are unable to contract for the     production of materials in <font color="blue">sufficient quantity</font> and of <font color="blue">sufficient quality on</font>     acceptable terms, our planned <font color="blue">clinical trials</font> may be <font color="blue">significant</font>ly delayed</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font><font color="blue">delays could postpone</font> the filing of our IND <font color="blue"><font color="blue">application</font>s</font>     and/or the <font color="blue">initiation</font> of <font color="blue">clinical trials</font> that we have currently planned</td>
    </tr>
    <tr>
      <td>Our  third-party  <font color="blue">manufacture</font>rs may not be able to <font color="blue">comply with</font> the GMP     <font color="blue">regulations</font>,  other  applicable FDA <font color="blue">regulatory</font> <font color="blue">requirements</font> or similar     <font color="blue">regulations</font> applicable outside of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Additionally, if we are     required to enter into new supply <font color="blue">arrangements</font>, we may not be able to obtain     <font color="blue">approval from</font> the FDA of any <font color="blue">alternate supplier</font> in a <font color="blue">timely manner</font>, or at     all,  which  could  delay  or  prevent  the  clinical  <font color="blue">development</font> and     <font color="blue">commercialization</font>  of  any  related product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Failure of our     third-party <font color="blue">manufacture</font>rs or us to obtain <font color="blue">approval from</font> the FDA or to comply     with applicable <font color="blue">regulations</font> could result in sanctions being <font color="blue">imposed on us</font>,     including fines, civil penalties, delays in or failure to <font color="blue">grant marketing</font>     approval of our product <font color="blue">candidates</font>, injunctions, delays, suspension or     withdrawal of approvals, license revocation, seizures or recalls of products     and compounds, operating <font color="blue">restrictions</font> and <font color="blue">criminal <font color="blue">prosecution</font>s</font>, any of     which could <font color="blue">significant</font>ly and <font color="blue">adversely affect</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>most  of  our  expected  future  revenues are <font color="blue">contingent upon</font>     <font color="blue">collaborative</font>  and license <font color="blue">agreement</font>s, we might not meet our strategic     <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate revenue</font> in the near <font color="blue">term depends on</font> our ability to     enter into <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">agreement</font>s with <font color="blue">third parties</font> and to     maintain the <font color="blue">agreement</font>s we currently have in place</td>
    </tr>
    <tr>
      <td>Our ability to enter     into new <font color="blue">collaboration</font>s and the revenue, if any, that may be recognized     under these <font color="blue">collaboration</font>s is <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>If we are unable to enter     into new <font color="blue">collaboration</font>s, our business <font color="blue">prospects could</font> be harmed, which could     have an <font color="blue">immediate adverse</font> effect on the <font color="blue">trading price</font> of our stock</td>
    </tr>
    <tr>
      <td>To date, most of our revenues have been related to the <font color="blue">research phase</font> of     each  of our <font color="blue">collaborative</font> <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Such revenues are for specified     periods, and the impact of <font color="blue"><font color="blue">such revenue</font>s on</font> our results of <font color="blue">operations</font> is     <font color="blue">partially offset by corresponding research costs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>the <font color="blue">completion</font>     of the research       15     ______________________________________________________________________       phase of each <font color="blue">collaborative</font> <font color="blue">agreement</font>, <font color="blue">additional</font> revenues may come only     from <font color="blue">milestone payment</font>s and royalties, which may not be paid, if at all,     until some time well into the future</td>
    </tr>
    <tr>
      <td>The risk is <font color="blue">heightened due</font> to the fact     that  <font color="blue">unsuccessful</font> research efforts may preclude us from receiving any     <font color="blue">milestone payment</font>s under these <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Our receipt of <font color="blue">revenues from</font>     <font color="blue">collaborative</font> <font color="blue">arrangements</font> is also <font color="blue">significant</font>ly affected by the timing of     <font color="blue">efforts expended by us</font> and our <font color="blue"><font color="blue">collaborator</font>s</font> and the timing of <font color="blue">lead compound</font>     <font color="blue">identification</font></td>
    </tr>
    <tr>
      <td>In late 2001, we recorded the <font color="blue">first <font color="blue">revenue from</font> achievement</font>     of <font color="blue">milestones</font> in both the Pfizer and Johnson &amp; Johnson <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>In     addition, we have <font color="blue">subsequently</font> received <font color="blue">milestone payment</font>s from Novartis,     Daiichi,  Merck  and SeroNodtta Under many <font color="blue">agreement</font>s, however, milestone     <font color="blue">payments may</font> not be <font color="blue">earned until</font> the <font color="blue">collaborator</font> has <font color="blue">advanced products into</font>     <font color="blue">clinical testing</font>, which may never occur or may not occur until some time     well into the future</td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue">generate revenue</font> under our     <font color="blue">collaboration</font>s  when  and  in  <font color="blue">accordance with</font> our <font color="blue">expectations</font> or the     <font color="blue">expectations</font> of <font color="blue">industry analysts</font>, this <font color="blue">failure could harm</font> our business and     have an <font color="blue">immediate adverse</font> effect on the <font color="blue">trading price</font> of our stock</td>
    </tr>
    <tr>
      <td>Our business requires us to <font color="blue">generate meaningful <font color="blue">revenue from</font> royalties</font> and     licensing  <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>To date, we have not received any <font color="blue">revenue from</font>     royalties for the <font color="blue">commercial sale</font> of drugs, and we do not know when we will     receive any <font color="blue">such revenue</font>, if at all</td>
    </tr>
    <tr>
      <td>Likewise, we have not licensed any lead     compounds or drug <font color="blue">development</font> <font color="blue">candidates</font> to <font color="blue">third parties</font>, and we do not     know whether any <font color="blue">such license will</font> be <font color="blue">entered into on</font> acceptable terms in     the future, if at all</td>
    </tr>
    <tr>
      <td>If  our  current  corporate  <font color="blue">collaboration</font>s  or license <font color="blue">agreement</font>s are     <font color="blue">unsuccessful</font>, our research and <font color="blue">development</font> efforts could be delayed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">strategy depends upon</font> the formation and <font color="blue">susta<font color="blue">inability</font></font> of multiple     <font color="blue">collaborative</font> <font color="blue">arrangements</font> and license <font color="blue">agreement</font>s with <font color="blue">third parties</font> in the     future</td>
    </tr>
    <tr>
      <td>We rely on these <font color="blue">arrangements</font> for not only financial resources, but     also for expertise that we expect to need in the future relating to clinical     trials, manufacturing, sales and marketing, and for licenses to <font color="blue">technology</font>     rights</td>
    </tr>
    <tr>
      <td>To  date, we have entered into several such <font color="blue">arrangements</font> with     corporate <font color="blue"><font color="blue">collaborator</font>s</font>; however, we do not know if such <font color="blue">third parties</font> will     <font color="blue">dedicate sufficient resources</font> or if any <font color="blue">development</font> or <font color="blue">commercialization</font>     efforts by <font color="blue">third parties</font> will be successful</td>
    </tr>
    <tr>
      <td>Should a <font color="blue">collaborative</font> partner     fail to develop or <font color="blue">commercialize</font> a compound or product to which it has     rights  from us for any reason including corporate restructuring, such     <font color="blue">failure might delay ongoing research</font> and <font color="blue">development</font> efforts at Rigel,     because we might not receive any future <font color="blue">milestone payment</font>s, and we would not     receive any <font color="blue">royalties <font color="blue">associated with</font> such compound</font> or product</td>
    </tr>
    <tr>
      <td>In addition,     the <font color="blue">continuation</font> of some of our partnered <font color="blue">drug discovery</font> and <font color="blue">development</font>     programs  may  be  <font color="blue">dependent</font>  on the <font color="blue">periodic renewal</font> of our corporate     <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>The <font color="blue">research phase</font> of our <font color="blue">collaboration</font> with Johnson &amp; Johnson ended in     <font color="blue">December </font>2003, and the <font color="blue">research phase</font>s conducted at our <font color="blue"><font color="blue">facilities</font> under</font> our     broad <font color="blue">collaboration</font> with Novartis ended in July 2004</td>
    </tr>
    <tr>
      <td>The <font color="blue">research phase</font> of     our corporate <font color="blue">collaboration</font> <font color="blue">agreement</font> with Daiichi ended in August 2005</td>
    </tr>
    <tr>
      <td>In     November 2004,  we signed a new corporate <font color="blue">collaboration</font> with Merck, in     January 2005 we signed an <font color="blue">additional</font> <font color="blue">collaboration</font> with Pfizer, and in     October 2005  we signed an <font color="blue">additional</font> <font color="blue">collaboration</font> with SeroNodtta <font color="blue">These     </font><font color="blue">agreement</font>s could be <font color="blue">terminated by</font> the other party, and we may not be able to     renew these <font color="blue">collaboration</font>s on acceptable terms, if at all, or negotiate     <font color="blue">additional</font> corporate <font color="blue">collaboration</font>s on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If these     <font color="blue">collaboration</font>s terminate or are not renewed, any <font color="blue">resultant loss</font> of revenues     from these <font color="blue">collaboration</font>s or loss of the expertise of our <font color="blue">collaborative</font>     partners could <font color="blue">adversely affect</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Conflicts  </font>also  might  arise  with  <font color="blue"><font color="blue">collaborative</font> partners</font> concerning     <font color="blue">proprietary</font> rights to <font color="blue">particular compounds</font></td>
    </tr>
    <tr>
      <td>While our existing <font color="blue">collaborative</font>     <font color="blue">agreement</font>s typically provide that we retain <font color="blue">milestone payment</font>s and royalty     <font color="blue">rights <font color="blue">with respect</font></font> to drugs developed <font color="blue">from certain derivative compounds</font>,     any such payments or <font color="blue">royalty <font color="blue">rights may</font></font> be <font color="blue">at reduced rates</font>, and disputes     may arise over the <font color="blue">application</font> of <font color="blue">derivative payment provisions</font> to such     drugs, and we may not be successful in <font color="blue">such disputes</font></td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       We are also a party to various license <font color="blue">agreement</font>s that <font color="blue">give us rights</font> to use     specified  <font color="blue">technologies</font> in our research and <font color="blue">development</font> processes</td>
    </tr>
    <tr>
      <td>The     <font color="blue">agreement</font>s pursuant to which we have in-licensed <font color="blue">technology</font> permit our     <font color="blue">licensors</font> to terminate the <font color="blue">agreement</font>s under certain circumstances</td>
    </tr>
    <tr>
      <td>If we are     not  able  to  continue  to  license  these and future <font color="blue">technologies</font> on     <font color="blue">commercially reasonable terms</font>, our product <font color="blue">development</font> and <font color="blue">research may</font> be     delayed</td>
    </tr>
    <tr>
      <td>If conflicts arise between our <font color="blue"><font color="blue">collaborator</font>s</font> or advisors and us, any of them     may act in their self-interest, which may be adverse to our <font color="blue">stockholders</font>’     interests</td>
    </tr>
    <tr>
      <td>If conflicts arise <font color="blue">between us</font> and our corporate <font color="blue"><font color="blue">collaborator</font>s</font> or scientific     advisors,  the other party may act in its self-interest and not in the     interest  of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Some of our corporate <font color="blue"><font color="blue">collaborator</font>s</font> are     conducting multiple product <font color="blue">development</font> efforts within each disease area     that is the subject of the <font color="blue">collaboration</font> with us or may be acquired or     merged  with  a  company  having  a  <font color="blue">competing program</font></td>
    </tr>
    <tr>
      <td>In some of our     <font color="blue">collaboration</font>s, we have agreed not to conduct, in<font color="blue">dependent</font>ly or with any     <font color="blue">third party</font>, any research that is <font color="blue"><font color="blue">competitive</font> with</font> the <font color="blue">research conducted</font>     under our <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaborator</font>s</font>, however, may develop, either     alone or <font color="blue">with others</font>, products in related fields that are <font color="blue"><font color="blue">competitive</font> with</font>     the  products  or  potential  products  that  are the subject of these     <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Competing </font>products, either developed by our <font color="blue"><font color="blue">collaborator</font>s</font> or     to which our <font color="blue"><font color="blue">collaborator</font>s</font> have rights, may result in their withdrawal of     support for our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If  any of our corporate <font color="blue"><font color="blue">collaborator</font>s</font> were to breach or terminate its     <font color="blue">agreement</font> with us or <font color="blue">otherwise fail</font> to conduct the <font color="blue">collaborative</font> <font color="blue">activities</font>     <font color="blue">successfully</font> and in a <font color="blue">timely manner</font>, the preclinical or clinical <font color="blue">development</font>     or <font color="blue">commercialization</font> of the affected product <font color="blue">candidates</font> or <font color="blue">research programs</font>     could be delayed or terminated</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> do not control the amount and     timing of resources that our corporate <font color="blue"><font color="blue">collaborator</font>s</font> devote to our programs     or  potential  products</td>
    </tr>
    <tr>
      <td>We  do  not  know  <font color="blue">whether current</font> or future     <font color="blue"><font color="blue">collaborative</font> partners</font>, if any, might pursue <font color="blue">alternative</font> <font color="blue">technologies</font> or     develop <font color="blue">alternative</font> <font color="blue">products either</font> on their own or in <font color="blue">collaboration</font> with     others, including our <font color="blue">competitors</font>, as a means for developing <font color="blue">treatments</font> for     the diseases targeted by <font color="blue">collaborative</font> <font color="blue">arrangements</font> with us</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent</font> on <font color="blue">intellectual</font> property rights held by us and     <font color="blue">third parties</font>, and our interest in <font color="blue">such rights</font> is complex and uncertain</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> to a large part on our own, our licensees’ and our     <font color="blue">licensors</font>’ ability to obtain and <font color="blue">defend patents</font> for each party’s respective     <font color="blue">technologies</font> and the compounds and other products, if any, resulting from     the  <font color="blue">application</font> of such <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We have over 150 pending patent     <font color="blue"><font color="blue">application</font>s</font> and over 50 <font color="blue">issued patents</font> in the <font color="blue">United States</font> that are owned     or  <font color="blue">exclusively licensed</font> in our <font color="blue">field as well as pending corresponding</font>     foreign patent <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>For     example, we may be involved in <font color="blue">interferences</font> before the <font color="blue">United States</font> Patent     and  Trademark  Office</td>
    </tr>
    <tr>
      <td><font color="blue">Interferences </font>are complex and <font color="blue">expensive legal</font>     <font color="blue">proceedings</font>  and  there  is no assurance we will be successful in such     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>An interference could result in our losing our <font color="blue">patent rights</font>     and/or  our  freedom  to  operate and/or require us to pay <font color="blue">significant</font>     royalties</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">uncertainty</font> may result because <font color="blue">no consistent policy</font>     regarding the breadth of legal claims allowed in bio<font color="blue">technology</font> patents has     emerged  to date</td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot predict</font> the breadth of claims     allowed in our or other companies’ patents</td>
    </tr>
    <tr>
      <td>·       Because the degree of future protection for our <font color="blue">proprietary</font> rights     is uncertain, we <font color="blue">cannot ensure</font> that:       ·       we were the first to make the <font color="blue">inventions</font> covered by each of our     pending patent <font color="blue"><font color="blue">application</font>s</font>;       ·       we were the first to file patent <font color="blue"><font color="blue">application</font>s</font> for these <font color="blue">inventions</font>;       17     ______________________________________________________________________       ·        others  will not in<font color="blue">dependent</font>ly develop similar or <font color="blue">alternative</font>     <font color="blue">technologies</font> or duplicate any of our <font color="blue">technologies</font>;       ·        any  of our pending patent <font color="blue"><font color="blue">application</font>s</font> will result in issued     patents;       ·       any <font color="blue">patents issued</font> to us or our <font color="blue"><font color="blue">collaborator</font>s</font> will provide a basis     for commercially-viable products or <font color="blue">will provide us with</font> any <font color="blue">competitive</font>     <font color="blue">advantages</font> or will not be challenged by <font color="blue">third parties</font>;       ·        we  will develop <font color="blue">additional</font> <font color="blue">proprietary</font> <font color="blue">technologies</font> that are     patentable; or       ·       the patents of <font color="blue">others will</font> not have a negative effect on our ability     to do business</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">trade secrets</font></font> to protect <font color="blue">technology</font> where we believe patent     protection is not <font color="blue">appropriate</font> or obtainable</td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font> are     <font color="blue">difficult</font>  to  protect</td>
    </tr>
    <tr>
      <td>While we require employees, <font color="blue"><font color="blue">collaborator</font>s</font> and     <font color="blue">consultants</font> to enter into <font color="blue">confidential</font>ity <font color="blue">agreement</font>s, we may not be able to     <font color="blue">adequately protect</font> our <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information in the     event of any <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> or the lawful <font color="blue">development</font> by     others of such information</td>
    </tr>
    <tr>
      <td>We are a party to certain in-license <font color="blue">agreement</font>s that are important to our     business, and we <font color="blue">generally</font> do not control the <font color="blue">prosecution</font> of in-licensed     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Accordingly, we are unable to exercise the same degree of     control  over  this  <font color="blue">intellectual</font>  property  as  we  <font color="blue">exercise over</font> our     internally-developed <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Moreover, some of our <font color="blue">academic institution</font>     <font color="blue">licensors</font>, research <font color="blue"><font color="blue">collaborator</font>s</font> and <font color="blue">scientific advisors</font> have rights to     <font color="blue">publish data</font> and information in which we have rights</td>
    </tr>
    <tr>
      <td>If we cannot maintain     the <font color="blue">confidential</font>ity of our <font color="blue">technology</font> and other <font color="blue">confidential</font> information in     <font color="blue">connection with</font> our <font color="blue">collaboration</font>s, then our ability to receive patent     protection or protect our <font color="blue">proprietary</font> information will be impaired</td>
    </tr>
    <tr>
      <td>In     addition,  some  of the <font color="blue">technology</font> we have <font color="blue">licensed relies on patented</font>     <font color="blue">inventions</font> developed using US <font color="blue"><font color="blue">government</font> resources</font></td>
    </tr>
    <tr>
      <td>The US <font color="blue">government</font>     retains certain rights, as defined by law, in <font color="blue">such patents</font>, and may choose     to exercise <font color="blue">such rights</font></td>
    </tr>
    <tr>
      <td>Certain of our in-licenses may be terminated if we     fail to meet specified <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>If we fail to meet such <font color="blue">obligations</font> and     any of our <font color="blue">licensors</font> exercise their <font color="blue">termination rights</font>, we <font color="blue">could lose</font> our     rights  under  those  <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>If we lose any of our rights, it may     <font color="blue">adversely affect</font> the way we conduct our business</td>
    </tr>
    <tr>
      <td>In addition, because     certain of our licenses are <font color="blue">sublicenses</font>, the actions of our <font color="blue">licensors</font> may     affect our <font color="blue">rights under</font> those licenses</td>
    </tr>
    <tr>
      <td>If a dispute arises regarding the <font color="blue">infringement</font> or <font color="blue">misappropriation</font> of the     <font color="blue">proprietary</font> rights of others, such dispute could be costly and result in     delays in our research and <font color="blue">development</font> <font color="blue">activities</font> and partnering</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will also depend</font>, in part, on our ability to operate without     infringing or <font color="blue">misappropriating</font> the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>There are     many <font color="blue">issued patents</font> and patent <font color="blue"><font color="blue">application</font>s</font> filed by <font color="blue">third parties</font> relating     to  products or processes that are similar or identical to ours or our     <font color="blue">licensors</font>, and <font color="blue">others may</font> be filed in the future</td>
    </tr>
    <tr>
      <td>There can be no assurance     that our <font color="blue">activities</font>, or those of our <font color="blue">licensors</font>, will not <font color="blue">infringe patents</font>     owned by others</td>
    </tr>
    <tr>
      <td>We believe that there may be <font color="blue">significant</font> <font color="blue">litigation</font> in the     industry regarding patent and other <font color="blue">intellectual</font> property rights, and we do     not  know  if  we or our <font color="blue"><font color="blue">collaborator</font>s</font> would be successful in any such     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">legal action against</font> our <font color="blue"><font color="blue">collaborator</font>s</font> or us claiming     damages or seeking to enjoin commercial <font color="blue">activities</font> relating to the affected     products, our methods or processes could:       ·       require our <font color="blue"><font color="blue">collaborator</font>s</font> or us to obtain a license to continue to     use, <font color="blue">manufacture</font> or market the affected products, methods or processes,     which may not be available on <font color="blue">commercially reasonable terms</font>, if at all;       ·       <font color="blue">prevent us from using</font> the subject matter claimed in the patents held     by others;       ·       subject us to <font color="blue">potential <font color="blue">liability</font></font> for damages;       18     ______________________________________________________________________       ·        consume a substantial portion of our managerial and financial     resources; and       ·       result in <font color="blue">litigation</font> or administrative <font color="blue">proceedings</font> that may be     costly, whether we win or lose</td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">regulatory</font> approval to <font color="blue">market products</font> in the     United  States and foreign <font color="blue">jurisdictions</font>, we might not be permitted to     <font color="blue">commercialize</font> products from our research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Due, in part, to the <font color="blue">early stage</font> of our product candidate research and     <font color="blue">development</font> process, we <font color="blue">cannot predict</font> whether <font color="blue">regulatory</font> clearance will be     obtained for any product that we, or our <font color="blue"><font color="blue">collaborative</font> partners</font>, hope to     develop</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of <font color="blue">regulatory</font> <font color="blue">requirements</font> typically takes many years,     is  <font color="blue">dependent</font> upon the type, <font color="blue">complexity</font> and novelty of the product and     requires  the  <font color="blue">expenditure</font>  of  substantial  resources</td>
    </tr>
    <tr>
      <td>Of particular     significance to us are the <font color="blue">requirements</font> relating to research and <font color="blue">development</font>     and testing</td>
    </tr>
    <tr>
      <td>Before commencing <font color="blue">clinical trials</font> in humans in the <font color="blue">United States</font>, we, or our     <font color="blue"><font color="blue">collaborative</font> partners</font>, will need to submit and receive <font color="blue">approval from</font> the     FDA of an IND Clinical trials are subject to oversight by institutional     <font color="blue">review boards</font> and the FDA and:       ·        must be conducted in conformance with the FDA’s good clinical     practices and other applicable <font color="blue">regulations</font>;       ·       must meet <font color="blue">requirements</font> for <font color="blue">institutional review board oversight</font>;       ·       must meet <font color="blue">requirements</font> for <font color="blue">informed consent</font>;       ·       are subject to continuing FDA oversight;       ·       may require large numbers of <font color="blue">test subjects</font>; and       ·       may be <font color="blue">suspended by us</font>, our <font color="blue"><font color="blue">collaborator</font>s</font> or the FDA at any time if     it is believed that the <font color="blue">subjects participating</font> in these trials are being     exposed to unacceptable <font color="blue">health risks</font> or if the FDA <font color="blue">finds deficiencies</font> in the     IND or the conduct of these trials</td>
    </tr>
    <tr>
      <td>While we have stated that we intend to file <font color="blue">additional</font> INDs, this is only a     statement of intent, and we may not be able to do so because we may not be     able to identify potential product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In addition, the FDA may not     approve any IND in a <font color="blue">timely manner</font>, or at all</td>
    </tr>
    <tr>
      <td>Before receiving FDA approval to market a product, we <font color="blue">must demonstrate</font> that     the  product  is  safe and <font color="blue">effective</font> in the <font color="blue">patient population</font> and the     <font color="blue">indication</font> that will be treated</td>
    </tr>
    <tr>
      <td>Data obtained <font color="blue">from preclinical</font> and clinical     <font color="blue">activities</font> are susceptible to <font color="blue">varying interpretations</font> that <font color="blue">could delay</font>,     limit or prevent <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>In addition, delays or <font color="blue">rejections may</font>     be encountered based upon <font color="blue">additional</font> <font color="blue">government</font> regulation from future     <font color="blue">legislation</font> or <font color="blue">administrative action</font> or changes in FDA <font color="blue">policy during</font> the     period of product <font color="blue">development</font>, <font color="blue">clinical trials</font> and FDA <font color="blue">regulatory</font> review</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  <font color="blue">comply with</font> applicable FDA or other applicable <font color="blue">regulatory</font>     <font color="blue">requirements</font> may result in criminal <font color="blue">prosecution</font>, civil penalties, recall or     seizure  of  products,  total  or  <font color="blue">partial suspension</font> of production or     injunction,  as  well as other <font color="blue">regulatory</font> action against our potential     products or us</td>
    </tr>
    <tr>
      <td>Additionally, we have limited experience in conducting and     managing the <font color="blue">clinical trials</font> <font color="blue">necessary</font> to obtain <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>If  <font color="blue">regulatory</font> approval of a product is granted, this <font color="blue">approval will</font> be     limited to those <font color="blue">indication</font>s or disease states and <font color="blue">conditions</font> for which the     product is demonstrated through <font color="blue">clinical trials</font> to be safe and <font color="blue">efficacious</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that any compound developed by us, alone or <font color="blue">with others</font>,     will prove to be safe and <font color="blue">efficacious</font> in <font color="blue">clinical trials</font> and will meet all     of  the applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> needed to receive marketing     approval</td>
    </tr>
    <tr>
      <td>Outside  the  <font color="blue">United States</font>, our ability, or that of our <font color="blue">collaborative</font>     partners, to market a product is <font color="blue">contingent upon</font> receiving a marketing     <font color="blue">authorization from</font> the <font color="blue">appropriate</font> <font color="blue">regulatory</font> authorities</td>
    </tr>
    <tr>
      <td><font color="blue">This       </font>19     ______________________________________________________________________       foreign <font color="blue">regulatory</font> <font color="blue">approval process</font> typically includes all of the risks     <font color="blue">associated with</font> FDA <font color="blue">approval described</font> above and may also include <font color="blue">additional</font>     risks</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> develop <font color="blue">technologies</font> that are more <font color="blue">effective</font> than ours,     our <font color="blue">commercial opportunity will</font> be reduced or eliminated</td>
    </tr>
    <tr>
      <td>The bio<font color="blue">technology</font> and <font color="blue"><font color="blue">pharmaceutical</font> industries</font> are intensely <font color="blue">competitive</font>     and subject to rapid and <font color="blue">significant</font> technological change</td>
    </tr>
    <tr>
      <td>Many of the drugs     that  we  are  attempting  to <font color="blue">discover will</font> be <font color="blue">competing with existing</font>     therapies</td>
    </tr>
    <tr>
      <td>In addition, a number of companies are pursuing the <font color="blue">development</font>     of <font color="blue"><font color="blue">pharmaceutical</font>s</font> that target the <font color="blue">same diseases</font> and <font color="blue">conditions</font> that we are     targeting</td>
    </tr>
    <tr>
      <td>We  <font color="blue">face competition from <font color="blue">pharmaceutical</font></font> and bio<font color="blue">technology</font>     <font color="blue">companies both</font> in the <font color="blue">United States</font> and abroad</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may utilize discovery <font color="blue">technologies</font> and <font color="blue">techniques</font> or partner     with <font color="blue"><font color="blue">collaborator</font>s</font> in order to develop products more rapidly or <font color="blue">successfully</font>     than we, or our <font color="blue"><font color="blue">collaborator</font>s</font>, are able to do</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font>,     <font color="blue">particularly</font> large <font color="blue">pharmaceutical</font> companies, have <font color="blue">substantially</font> greater     financial, technical and human resources than we do</td>
    </tr>
    <tr>
      <td>In addition, academic     institutions, <font color="blue">government</font> agencies and other public and private <font color="blue">organizations</font>     conducting <font color="blue">research may</font> seek <font color="blue">patent protection</font> <font color="blue">with respect</font> to <font color="blue">potentially</font>     <font color="blue">competitive</font>  products  or  <font color="blue">technologies</font>  and  may  <font color="blue">establish exclusive</font>     <font color="blue">collaborative</font> or <font color="blue">licensing <font color="blue">relationships</font> with</font> our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We believe that our ability to compete is <font color="blue">dependent</font>, in part, upon our     ability to create, maintain and license scientifically-advanced <font color="blue">technology</font>     and upon our and our <font color="blue"><font color="blue">collaborator</font>s</font>’ ability to develop and <font color="blue">commercialize</font>     <font color="blue"><font color="blue">pharmaceutical</font> products</font> based on this <font color="blue">technology</font>, as well as our ability to     attract  and  retain  <font color="blue">qualified personnel</font>, obtain <font color="blue">patent protection</font> or     otherwise develop <font color="blue">proprietary</font> <font color="blue">technology</font> or processes and <font color="blue">secure sufficient</font>     capital  resources  for  the  expected substantial time <font color="blue">period between</font>     <font color="blue">technological conception</font> and <font color="blue">commercial sale</font>s of <font color="blue">products based upon</font> our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">failure by us</font> or any of our <font color="blue"><font color="blue">collaborator</font>s</font> in any of those     <font color="blue">areas may prevent</font> the successful <font color="blue">commercialization</font> of our <font color="blue">potential drug</font>     targets</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> might develop <font color="blue">technologies</font> and drugs that are more <font color="blue">effective</font>     or <font color="blue">less costly than</font> any that are being developed by us or that would render     our <font color="blue">technology</font> and <font color="blue">potential drug</font>s obsolete and non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>In addition,     our <font color="blue">competitors</font> may succeed in obtaining the approval of the FDA or other     <font color="blue">regulatory</font> agencies for product <font color="blue">candidates</font> more rapidly</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>that     complete <font color="blue">clinical trials</font>, obtain required <font color="blue">regulatory</font> agency approvals and     commence <font color="blue">commercial sale</font> of their drugs before their <font color="blue">competitors</font> may achieve     a  <font color="blue">significant</font> <font color="blue">competitive</font> advantage, including certain patent and FDA     marketing exclusivity rights that would delay or prevent our ability to     market  certain  products</td>
    </tr>
    <tr>
      <td>Any  drugs resulting from our research and     <font color="blue">development</font> efforts, or from our <font color="blue">joint efforts with</font> our existing or future     <font color="blue"><font color="blue">collaborative</font> partners</font>, might not be able to compete <font color="blue">successfully</font> with     <font color="blue">competitors</font>’ existing or <font color="blue">future products</font> or obtain <font color="blue">regulatory</font> approval in     the <font color="blue">United States</font> or elsewhere</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate revenue</font>s will be diminished if our <font color="blue">collaborative</font>     partners  fail  to  obtain  acceptable  prices or an <font color="blue">adequate level</font> of     <font color="blue">reimbursement</font> for products from third-party payors or <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>The drugs we hope to develop may be <font color="blue">rejected by</font> the <font color="blue">marketplace due</font> to many     factors, including cost</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercially exploit</font> a drug may be     limited due to the <font color="blue">continuing efforts</font> of <font color="blue">government</font> and third-party payors     to contain or reduce the costs of <font color="blue">health care through various</font> means</td>
    </tr>
    <tr>
      <td>For     example, in some foreign markets, pricing and <font color="blue">profitability</font> of <font color="blue">prescription</font>     <font color="blue"><font color="blue">pharmaceutical</font>s</font> are subject to <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, we     expect  that  there  <font color="blue">will continue</font> to be a number of federal and state     proposals to implement similar <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>In addition, increasing     <font color="blue">emphasis on managed care</font> in the <font color="blue">United States</font> <font color="blue">will likely continue</font> to put     <font color="blue">pressure on</font> the pricing of <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Cost <font color="blue">control initiatives</font>     <font color="blue">could decrease</font> the price that any of our <font color="blue"><font color="blue">collaborator</font>s</font> would receive for any     products in       20     ______________________________________________________________________       the future</td>
    </tr>
    <tr>
      <td>Further, cost <font color="blue">control initiatives</font> could <font color="blue">adversely affect</font> our     <font color="blue"><font color="blue">collaborator</font>s</font>’ ability to <font color="blue">commercialize</font> our products and our ability to     realize <font color="blue">royalties from</font> this <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> <font color="blue"><font color="blue">pharmaceutical</font> products</font> with <font color="blue"><font color="blue">collaborator</font>s</font> may     depend, in part, on the extent to which <font color="blue">reimbursement</font> for the <font color="blue">products will</font>     be <font color="blue">available from</font>:       ·       <font color="blue">government</font> and <font color="blue">health administration authorities</font>;       ·       <font color="blue">private health insurers</font>; and       ·       other third-party payors</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font> <font color="blue">uncertainty</font>  exists  as  to  the  <font color="blue">reimbursement</font> status of     newly-approved healthcare products</td>
    </tr>
    <tr>
      <td>Third-party payors, including Medicare,     are  <font color="blue">challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>and other third-party payors increasingly are attempting to     contain  healthcare  costs  <font color="blue">by limiting both coverage</font> and the level of     <font color="blue">reimbursement</font> for new drugs and by refusing, in some cases, to provide     coverage for uses of <font color="blue">approved products</font> for disease <font color="blue">indication</font>s for which the     FDA has not <font color="blue">granted labeling approval</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">insurance coverage may</font>     not be available to patients for any products we discover and develop, alone     or with <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> and other third-party payors do not     <font color="blue">provide adequate coverage</font> and <font color="blue">reimbursement</font> levels for our products, the     market <font color="blue">acceptance</font> of these <font color="blue">products may</font> be reduced</td>
    </tr>
    <tr>
      <td>If <font color="blue">product <font color="blue">liability</font> lawsuits</font> are <font color="blue">successfully</font> brought against us, we may     incur substantial <font color="blue">liabilities</font> and may be required to limit <font color="blue">commercialization</font>     of our products</td>
    </tr>
    <tr>
      <td>The testing and marketing of <font color="blue">medical products</font> entail an <font color="blue">inherent risk</font> of     product  <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font> defend ourselves against     product  <font color="blue">liability</font>  claims, we may incur substantial <font color="blue">liabilities</font> or be     required to limit <font color="blue">commercialization</font> of our <font color="blue">products although</font> we are not     <font color="blue">currently aware</font> of any specific causes for concern <font color="blue">with respect</font> to clinical     <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>We currently do not have product <font color="blue">liability</font> insurance, and     our  <font color="blue">inability</font>  to obtain sufficient product <font color="blue">liability</font> insurance at an     acceptable cost to protect against potential product <font color="blue">liability</font> claims could     prevent or inhibit the <font color="blue">commercialization</font> of <font color="blue"><font color="blue">pharmaceutical</font> products</font> we     develop,  alone  or with corporate <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>We, or our corporate     <font color="blue"><font color="blue">collaborator</font>s</font>, might not be able to obtain insurance at a reasonable cost,     if  at  all</td>
    </tr>
    <tr>
      <td>While  <font color="blue">under various circumstances</font> we are entitled to be     <font color="blue">indemnified against losses by</font> our corporate <font color="blue"><font color="blue">collaborator</font>s</font>, indemnification     may not be available or <font color="blue">adequate should</font> any claim arise</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> efforts will be <font color="blue">seriously jeopardized</font>, if we     are unable to attract and retain <font color="blue">key employees</font> and <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>As a small company with only 151 employees as of <font color="blue">December </font>31, 2005, our     <font color="blue">success depends on</font> the <font color="blue">continued contributions</font> of our <font color="blue">principal <font color="blue">management</font></font>     and  scientific  personnel  and on our ability to develop and maintain     important <font color="blue">relationships</font> with leading <font color="blue">academic institution</font>s, <font color="blue">scientists</font> and     companies  in  the  face of <font color="blue">intense competition</font> for <font color="blue">such personnel</font></td>
    </tr>
    <tr>
      <td>In     particular, our <font color="blue">research programs</font> depend on our ability to attract and     retain  highly  skilled  chemists,  other <font color="blue">scientists</font>, and <font color="blue">development</font>,     <font color="blue">regulatory</font> and <font color="blue">clinical personnel</font></td>
    </tr>
    <tr>
      <td>If we lose the services of any of our     personnel, our research and <font color="blue">development</font> efforts could be seriously and     <font color="blue">adversely affect</font>ed</td>
    </tr>
    <tr>
      <td>Our employees can terminate their <font color="blue">employment with us at</font>     any time</td>
    </tr>
    <tr>
      <td>We depend on various scientific <font color="blue">consultants</font> and advisors for the success and     <font color="blue">continuation</font> of our research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We work extensively with various scientific <font color="blue">consultants</font> and advisors</td>
    </tr>
    <tr>
      <td>The     <font color="blue">potential success</font> of our <font color="blue">drug discovery</font> and <font color="blue">development</font> programs depends, in     part, on continued <font color="blue">collaboration</font>s with certain of these <font color="blue">consultants</font> and     advisors</td>
    </tr>
    <tr>
      <td>We, and various members of our <font color="blue">management</font> and research staff, rely     on certain       21     ______________________________________________________________________       of these <font color="blue">consultants</font> and advisors for expertise in our research, <font color="blue">regulatory</font>     and clinical efforts</td>
    </tr>
    <tr>
      <td>Our <font color="blue">scientific advisors</font> are not our employees and may     have  <font color="blue">commitments</font>  to, or consulting or <font color="blue">advisory contracts with</font>, other     entities that may limit their <font color="blue">availability</font> to us</td>
    </tr>
    <tr>
      <td>We do not know if we will     be able to maintain such consulting <font color="blue">agreement</font>s or that <font color="blue">such scientific</font>     advisors  will  not  enter  into consulting <font color="blue">arrangements</font>, exclusive or     otherwise, with competing <font color="blue">pharmaceutical</font> or <font color="blue">bio<font color="blue">technology</font> companies</font>, any of     <font color="blue">which would</font> have a <font color="blue">detrimental impact on</font> our research <font color="blue">objectives</font> and could     have a material adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">use biological</font> and <font color="blue">hazardous materials</font> in a manner that causes injury     or <font color="blue">violates laws</font>, we may be liable for damages</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of     <font color="blue">potentially</font> harmful biological materials as well as <font color="blue">hazardous materials</font>,     <font color="blue">chemicals</font> and <font color="blue">various radioactive compounds</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot <font color="blue">completely</font> eliminate</font>     the  risk of <font color="blue">accidental <font color="blue">contamination</font></font> or <font color="blue">injury from</font> the use, storage,     handling or disposal of these materials</td>
    </tr>
    <tr>
      <td>In the event of <font color="blue">contamination</font> or     injury, we could be held liable for damages that result, and such <font color="blue">liability</font>     could exceed our resources</td>
    </tr>
    <tr>
      <td>We are also subject to federal, state and local     laws and <font color="blue">regulations</font> governing the use, storage, handling and disposal of     these materials and <font color="blue">specified waste products</font></td>
    </tr>
    <tr>
      <td>The cost of <font color="blue">compliance with</font>,     or  any  potential  violation  of, these laws and <font color="blue">regulations</font> could be     <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">facilities</font> are located near <font color="blue">known earthquake fault zones</font>, and the     occurrence of an earthquake or other <font color="blue">catastrophic disaster could</font> cause     damage to our <font color="blue">facilities</font> and equipment, which could require us to cease or     curtail <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">facilities</font>  are  located in the <font color="blue">San Francisco Bay Area </font>near known     earthquake  fault  zones and are vulnerable to <font color="blue">significant</font> <font color="blue">damage from</font>     <font color="blue">earthquakes</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also vulnerable</font> to <font color="blue">damage from</font> other types of <font color="blue">disasters</font>,     including fires, floods, power loss, communications failures and similar     events</td>
    </tr>
    <tr>
      <td>If any disaster were to occur, our ability to operate our business     at our <font color="blue">facilities</font> would be seriously, or <font color="blue">potentially</font> <font color="blue">completely</font>, impaired,     and our research could be lost or destroyed</td>
    </tr>
    <tr>
      <td>In addition, the unique nature     of  our research <font color="blue">activities</font> and of much of our <font color="blue">equipment could</font> make it     <font color="blue">difficult</font> for us to <font color="blue">recover from</font> a disaster</td>
    </tr>
    <tr>
      <td>The insurance we maintain may     not  be adequate to cover our losses resulting from <font color="blue">disasters</font> or other     business <font color="blue">interruptions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price may</font> be volatile, and our <font color="blue">stockholders</font>’ investment in our     <font color="blue">stock could decline</font> in value</td>
    </tr>
    <tr>
      <td>The  <font color="blue"><font color="blue">market price</font>s</font> for our securities and those of other bio<font color="blue">technology</font>     companies have been <font color="blue">highly volatile</font> and <font color="blue">may continue</font> to be <font color="blue">highly volatile</font>     in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors</font>, in addition to other <font color="blue">risk factors</font>     described in this section, may have a <font color="blue">significant</font> impact on the <font color="blue">market price</font>     of our <font color="blue">common stock</font>:       ·       the progress and success of preclinical <font color="blue">activities</font> (ie, studies,     <font color="blue">manufacture</font> of materials) and <font color="blue">clinical trials</font> of our product <font color="blue">candidates</font>     <font color="blue">conducted by us</font> or our <font color="blue"><font color="blue">collaborative</font> partners</font> or licensees;       ·       the receipt or failure to receive the <font color="blue">additional</font> funding <font color="blue">necessary</font>     to conduct our business;       ·       <font color="blue">selling by</font> large <font color="blue">stockholders</font>;       ·        <font color="blue">announcements</font>  of <font color="blue">technological innovations</font> or <font color="blue">new commercial</font>     <font color="blue">products by</font> our <font color="blue">competitors</font> or us;       ·       <font color="blue">development</font>s concerning <font color="blue">proprietary</font> rights, including patents;       ·       <font color="blue">development</font>s concerning our <font color="blue">collaboration</font>s;       ·       publicity regarding actual or <font color="blue">potential medical</font> results relating to     products under <font color="blue">development</font> by our <font color="blue">competitors</font> or us;       22     ______________________________________________________________________       ·       <font color="blue">regulatory</font> <font color="blue">development</font>s in the <font color="blue">United States</font> and foreign countries;       ·       <font color="blue">litigation</font>;       ·       economic and other <font color="blue">external factors</font> or other disaster or crisis; and       ·       period-to-period fluctuations in financial results</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">charter documents</font> and under <font color="blue">Delaware </font>law may     make an <font color="blue">acquisition</font> of us, which may be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font>, more     <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> and     bylaws, as well as provisions of <font color="blue">Delaware </font>law, could make it more <font color="blue">difficult</font>     for  a  third  party to acquire us, even if doing so <font color="blue">would benefit</font> our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These provisions:       ·       establish that members of the board of <font color="blue">directors</font> may be <font color="blue">removed only</font>     for cause upon the <font color="blue">affirmative vote</font> of <font color="blue">stockholders</font> owning a majority of our     <font color="blue">capital stock</font>;       ·       authorize the issuance of “blank check” preferred stock that could     be issued by our board of <font color="blue">directors</font> to increase the number of outstanding     shares and thwart a <font color="blue">takeover attempt</font>;       ·       limit who may call a <font color="blue">special meeting</font> of <font color="blue">stockholders</font>;       ·       prohibit stockholder action by written consent, thereby requiring     all <font color="blue">stockholder actions</font> to be taken at a meeting of our <font color="blue">stockholders</font>;       ·       <font color="blue">establish advance</font> notice <font color="blue">requirements</font> for <font color="blue">nominations</font> for election     to the board of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that can be acted upon at     <font color="blue">stockholder meetings</font>;       ·       provide for a board of <font color="blue">directors</font> with staggered terms; and       ·       provide that the authorized number of <font color="blue">directors</font> may be changed only     by a resolution of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>In addition, Section 203 of the <font color="blue">Delaware </font>General Corporation Law, which     imposes  certain  <font color="blue">restrictions</font>  relating  to  <font color="blue">transactions</font>  with major     <font color="blue">stockholders</font>, may discourage, delay or prevent a <font color="blue">third party</font> from acquiring     us</td>
    </tr>
  </tbody>
</table>